A partner application on Blackford Platform™, icobrain provides an FDA-cleared and CE-marked solution for easy and reliable access to MR and CT quantification for applications like multiple sclerosis, dementia, brain trauma and epilepsy. This allows for an accelerated interpretation, improved communication, and a better-informed clinical decision-making.


Improve patient communication and care

icobrain can assist with the communication between physicians and patients and aid in the earlier diagnosis and assessment of treatment response.

Optimize consistency and sensitivity of radiological reading

Starting from objective and standardized measurements to monitor neurological disorders strongly improves the inter
and intrarater variability of the radiological reading.

Save radiological reading time

The ever-increasing number of medical images puts a lot of pressure on radiologists. With icobrain, the reading of brain scans can be significantly reduced thanks to the seamless integration of reporting parameters and annotated images in the radiological workflow.


The icobrain ms software helps physicians assess (sub)clinical parameters and, therefore, enables the early prediction of disability progression, relapses and treatment response in individual patients with MS.

icobrain ms allows for the objective assessment of the lesion dissemination in space and time by:
• Detecting, quantifying and tracking the evolution of FLAIR white matter, T1 white matter hypointensities and contrast-enhancing T1 hyperintensities to evaluate disease activity.

• Reporting the distribution following the McDonald criteria (juxtacortical, periventricular, deep white matter and infratentorial).

icobrain ms provides precise and relevant brain atrophy measures by:
• Tracking the annualized brain volume changes for whole brain and gray matter to evaluate disease progression.

• Comparing brain volumes and volume changes to an age-and gender matched normative healthy population.

icobrain dm helps physicians with the differential diagnosis of the most common dementia types (Alzheimer’sDisease (AD), vascular dementia (VaD), dementia with Lewy Bodies (DLB) and Frontotemporal dementia (FTD).

icobrain dm uncovers abnormality patterns by:
• Quantifying and tracking the annualized brain volume changes of dementia-specific brain structures (frontal,
parietal, temporal and hippocampal cortex).

• Assessing the total FLAIR white matter hyperintensity burden.

• Comparing whole brain and ventricular volumes and volume changes to an age-and gender matched normative healthy population.

• Visualizing atrophy patterns in an intuitive dementia signature.

icobrain tbi for MR evaluates traumatic axial injuries (TAI) and atrophy in patients with mild to severe brain trauma. The icobrain tbi software, therefore, enables the early prediction of disability progression, and prompt treatment response.

icobrain tbi for MR allows for the detection of diffuse consequences of brain damage by:
• Detecting, quantifying and tracking the progression of FLAIR white matter hyperintensities.

• Assessing the distribution and change following the Adams-Gentry Classification (subcortical, cerebellum, corpus callosum and brain stem).

• Tracking the annualized changes for cortical and hippocampal volumes.

• Comparing brain volumes and volume changes to an age-and gender matched normative healthy population.

icobrain tbi for CT evaluates acute brain trauma on non-contrast CT scans. The icobrain tbi software enables the fast and standardized assessment of acute brain trauma by the automated assessment of intracranial injuries. icobrain tbi, therefore, bridges the gap between clinical practice and CT scoring systems, which can aid in the correct and prompt patient management.

icobrain tbi for CT allows for the detection of mass effects by:
• Detecting and quantifying hyperdensities.

• Assessing the cisternal CSF spaces.

• Measuring midline shift.

• Visualizing CSF space patterns in an intuitive bull’s eye graph.

• Comparing volumes to an age-and gender matched normative healthy population.

Schedule a demo


“In order to optimize individualized care and treatment efficacy, we have to understand how things change before permanent disability takes place. icobrain is a first step towards this goal.””

Dr. Mark Gudesblatt, M.D., Medical director of the Comprehensive MS Care Center at South Shore Neurologic Associates

“Like icobrain, brain biomarker measurements need to be extremely reproducible and sensitive enough to detect relevant clinical changes.”

Dr. Max Wintermark, Professor of Radiology and Chief of Neuroradiology at Stanford University Medical Center

“icobrain has been a really valuable addition to our clinical practice as patients can conceptually understand much better what we are looking for in their brain scans.”

Prof. Jeffrey Dunn, MD Professor of Clinical Neurology Department of Neurology and Neurosciences, Stanford University